Literature DB >> 28969840

Experimental cystic echinococcosis therapy: In vitro and in vivo combined 5-fluorouracil/albendazole treatment.

Patricia E Pensel1, Natalia Elissondo2, Guillermo Gambino2, Gabriela Ullio Gamboa3, J P Benoit4, María C Elissondo5.   

Abstract

Human cystic echinococcosis is a zoonosis caused by the larval stage of the tapeworm Echinococcus granulosus sensu lato (s. l.). Although benzimidazole compounds such as albendazole (ABZ) and mebendazole have been the cornerstone of chemotherapy for the disease, there is often no complete recovery after treatment. Hence, new strategies are required to improve treatment of human cystic echinococcosis. The goals of the current study were as follows: (i) to evaluate the in vitro efficacy of the 5-fluorouracil (5-FU) and ABZ combination against E. granulosus s. l. protoscoleces and cysts, (ii) to compare the clinical efficacy of 5-FU alone or in combination with ABZ in infected mice. The combination of 5-FU+ABZ had a stronger in vitro effect against larval stage than that did both drugs alone. Even at the lowest concentration of 5-FU+ABZ combination (1μg/ml), the reduction of the viability of protoscoleces and cysts was greater than that observed with drugs alone at 10μg/ml. The results were confirmed at the ultrastructural level by scanning electron microscopy. These data helped to justify the in vivo investigations assessing the therapeutic potential of the combination of 5-FU and ABZ suspension in CF-1 mice infected with E. granulosus sensu stricto (s. s.) metacestodes. Treatment with 5-FU (10mg/kg) or 5-FU (10mg/kg) + ABZ suspension (5mg/kg) reduced the weight of cysts recovered from mice compared with control groups. Interestingly, the effect of 5-FU given weekly for 5 consecutive weeks was comparable to that observed with ABZ suspension under a daily schedule during 30days. Co-administration of 5-FU with ABZ did not enhance the in vivo efficacy of drugs alone calculated in relation to cysts weights. However, the combination provoked greater ultrastructural alterations compared to the monotherapy. In conclusion, we demonstrated the efficacy of 5-FU either alone or co-administrated with ABZ against murine experimental cystic echinococcosis. Since 5-FU treatments did not cause toxic effect in mice, further in vivo studies will be performed by adjusting the dosage and the frequency of treatments.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-fluorouracil; Albendazole; Cystic echinococcosis; Echinococcus granulosus sensu stricto

Mesh:

Substances:

Year:  2017        PMID: 28969840     DOI: 10.1016/j.vetpar.2017.08.011

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  10 in total

1.  Effects of Zataria multiflora essential oil on the germinative cells of Echinococcus granulosus.

Authors:  Nasim Kowsari; Mohammad Moazeni; Ali Mohammadi
Journal:  Parasit Vectors       Date:  2021-05-17       Impact factor: 3.876

2.  In vitro Scolicidal Efficacy of 5-Fluorouracil and Radiation Against Protoscoleces of Echinococcus granulosus Sensu Lato.

Authors:  Pengfei Lu; Jun Li; Rui Mao; Hongzhi Qi; Liping Yang; Qin Zhou; Mengxiao Tian; Wenbao Zhang; Yongxing Bao
Journal:  Acta Parasitol       Date:  2022-02-03       Impact factor: 1.440

3.  Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections.

Authors:  Jun Li; Weisi Wang; Junmin Yao; Tian Wang; Shizhu Li; Wenjing Qi; Shuai Han; Yuan Ren; Zhisheng Dang; Xiumin Han; Gang Guo; Baoping Guo; Liqin Wang; Liping Duan; Wenbao Zhang
Journal:  EBioMedicine       Date:  2020-04-09       Impact factor: 8.143

4.  In vitro and in vivo effects of 3-bromopyruvate against Echinococcus metacestodes.

Authors:  Qi Xin; Miaomiao Yuan; Huanping Li; Xiaoxia Song; Jun Lu; Tao Jing
Journal:  Vet Res       Date:  2019-11-19       Impact factor: 3.683

5.  Joining forces: Leveraging novel combination therapies to combat infections with eukaryotic pathogens.

Authors:  Rachel E Ham; Lesly A Temesvari
Journal:  PLoS Pathog       Date:  2020-12-31       Impact factor: 6.823

6.  Practice of Surgical Treatment for Patients with Combined Echinococcosis of Chest and Abdominal Organs.

Authors:  Bekdaulet Akimniyazova; Galina Kausova; Temur Yeshmuratov; Daniyar Toksanbayev; Gulstan Esetova
Journal:  Tanaffos       Date:  2021-02

7.  Evaluation of the efficacy of Zataria multiflora essential oil versus albendazole in patients infected with liver cystic echinococcosis: A nonrandomized clinical trial.

Authors:  Arash Jafari; Mohammad Moazeni; Seyed Vahid Hosseini; Hajar Khazraei; Saeedeh Pourahmad
Journal:  J Res Med Sci       Date:  2021-12-22       Impact factor: 1.852

8.  Integrative Analysis of RNA Expression and Regulatory Networks in Mice Liver Infected by Echinococcus multilocularis.

Authors:  Tingli Liu; Hong Li; Yanping Li; Liqun Wang; Guoliang Chen; Guiting Pu; Xiaola Guo; William C Cho; Majid Fasihi Harandi; Yadong Zheng; Xuenong Luo
Journal:  Front Cell Dev Biol       Date:  2022-03-24

9.  2-Deoxy-D-glucose and combined 2-Deoxy-D-glucose/albendazole exhibit therapeutic efficacy against Echinococcus granulosus protoscoleces and experimental alveolar echinococcosis.

Authors:  Qi Xin; Wei Lv; Yunxi Xu; Yumei Luo; Caifang Zhao; Bichen Wang; Miaomiao Yuan; Huanping Li; Xiaoxia Song; Tao Jing
Journal:  PLoS Negl Trop Dis       Date:  2022-07-18

10.  In vitro and in vivo Effects of Artesunate on Echinococcus granulosus Protoscoleces and Metacestodes.

Authors:  Limei Wen; Guodong Lv; Jun Zhao; Shuai Lu; Yuehong Gong; Yafen Li; Haiya Zheng; Bei Chen; Huijing Gao; Chunyan Tian; Jianhua Wang
Journal:  Drug Des Devel Ther       Date:  2020-11-02       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.